Incyte Corp INCY:NASDAQ

Last Price$98.77Cboe Real-Time Last Sale as of 3:14PM ET 6/03/20
Cboe Real-Time Quotes
Realtime quote and/or trade prices are not sourced from all markets
Today's Change-2.13(2.11%)
Bid (Size)$98.72 (100)
Ask (Size)$98.86 (100)
Day Low / High$97.61 - 100.81
Volume1.1 M

Sector Update: Negative Sentiment Dragging Health Care Stocks Lower

1:59PM ET 4/03/2020 MT Newswires
Top Health Care Stocks

JNJ -0.41%

PFE +1.79%

ABT -0.60%

MRK -0.94%

AMGN -2.05%

Health care stocks were falling, with the NYSE Health Care Index declining 1% while the SPDR Health Care Select Sector ETF was down 1.3%. The Nasdaq Biotechnology index was dropping 1.2% this afternoon.

Among health care stocks moving on news:

(+) Incyte (INCY) was 2% higher after announcing plans for a late-stage trial of its ruxolitinib drug candidate as a potential treatment for a potential fatal immune reaction known as a cytokine storm in patients with COVID-19. The company also said it was increasing its production of ruxolitinib because of the COVID-19 pandemic.

In other sector news:

(+) electroCore (ECOR) rose almost 37% after the medical device company said it has submitted an emergency use authorization application to the US Food and Drug Administration allowing for the study and use of its gammaCore vagus nerve stimulation therapy for respiratory symptoms associated with COVID-19. The device previously received CE Mark authorization for certain respiratory indications, including asthma, bronchoconstriction, bronchospasm and COPD.

(-) La Jolla Pharmaceutical (LJPC) turned 2.6% lower this afternoon, giving back an earlier advance that followed the specialty drugmaker Friday saying it will provide its Giapreza medication for emergency use to help increase blood patients in patients with septic shock due to COVID-19. The drug recently was approved by European Commission but is not yet commercially available in the EU.

Price: 78.56, Change: +1.49, Percent Change: +1.93